EMA Begins Review of Enhertu Combination for First-Line Breast Cancer Therapy

Mon, 19 Jan 2026 10:15:49 +0000

Amsterdam, Monday 19 January 2026 The EMA has initiated a review of Enhertu with pertuzumab for first-line HER2-positive breast cancer, potentially updating a standard of care that has remained unchanged for over a decade.

Regulatory Approval on Silicon Polder

EMA Begins Review of Enhertu Combination for First-Line Breast Cancer Therapy